Detection of high-risk HPV 16 genotypes in cervical cancers using isothermal DNA amplification with electrochemical genosensor
Issued Date
2024-03-01
Resource Type
ISSN
00399140
Scopus ID
2-s2.0-85178169789
Journal Title
Talanta
Volume
269
Rights Holder(s)
SCOPUS
Bibliographic Citation
Talanta Vol.269 (2024)
Suggested Citation
Nakowong P., Chatchawal P., Chaibun T., Boonapatcharoen N., Promptmas C., Buajeeb W., Lee S.Y., Jearanaikoon P., Lertanantawong B. Detection of high-risk HPV 16 genotypes in cervical cancers using isothermal DNA amplification with electrochemical genosensor. Talanta Vol.269 (2024). doi:10.1016/j.talanta.2023.125495 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/91345
Title
Detection of high-risk HPV 16 genotypes in cervical cancers using isothermal DNA amplification with electrochemical genosensor
Other Contributor(s)
Abstract
Cervical cancer emerges as the third most prevalent types of malignancy among women on a global scale. Cervical cancer is significantly associated with the persistent infection of human papillomavirus (HPV) type 16. The process of diagnosing is crucial in order to prevent the progression of a condition into a malignant state. The early detection of cervical cancer through initial stage screening is of the utmost significance in both the prevention and effective management of this disease. The present detection methodology is dependent on quantitative polymerase chain reaction (qPCR), which necessitates the use of a costly heat cycler instrument. In this study, we report the development of an electrochemical DNA biosensor integrated with an isothermal recombinase polymerase amplification (RPA) reaction for the detection and identification of the high-risk HPV-16 genotype. The electrochemical biosensor exhibited a high degree of specificity and sensitivity, as evidenced by its limit of detection (LOD) of 0.23 copies/μL of HPV-16 DNA. The validity of this electrochemical platform was confirmed through the analysis of 40 cervical tissues samples, and the findings were consistent with those obtained through polymerase chain reaction (PCR) testing. Our straightforward electrochemical detection technology and quick turnaround time at 75 min make the assay suitable for point-of-care testing in low-resource settings.